AIM ImmunoTech has received a warning notification from NYSE American due to noncompliance with minimum stockholders' equity requirements. The company reported a stockholders' deficit of negative $3.9 million as of March 31, 2025, and has experienced losses in the past five fiscal years. NYSE American requires stockholders' equity of $4.0 million for companies with losses in three of four recent fiscal years, and $6.0 million for those with losses in five recent fiscal years. This follows a previous warning issued in December 2024. AIM has submitted a compliance plan that was accepted by NYSE American, giving the company until June 11, 2026, to meet requirements. The company's stock continues trading under symbol AIM, and the notice does not affect its business operations or SEC reporting requirements.
AIM ImmunoTech ha ricevuto una notifica di avvertimento dalla NYSE American a causa del mancato rispetto dei requisiti minimi di patrimonio netto degli azionisti. Al 31 marzo 2025, la societ脿 ha riportato un patrimonio netto negativo di 3,9 milioni di dollari e ha registrato perdite negli ultimi cinque esercizi fiscali. La NYSE American richiede un patrimonio netto di 4,0 milioni di dollari per le societ脿 con perdite in tre degli ultimi quattro esercizi fiscali, e di 6,0 milioni per quelle con perdite negli ultimi cinque esercizi. Questa notifica segue un precedente avvertimento emesso a dicembre 2024. AIM ha presentato un piano di conformit脿 accettato dalla NYSE American, che concede alla societ脿 tempo fino all'11 giugno 2026 per soddisfare i requisiti. Le azioni della societ脿 continuano a essere negoziate con il simbolo AIM, e la notifica non influisce sulle operazioni aziendali n茅 sugli obblighi di rendicontazione alla SEC.
AIM ImmunoTech ha recibido una notificaci贸n de advertencia por parte de NYSE American debido al incumplimiento de los requisitos m铆nimos de patrimonio neto de los accionistas. La compa帽铆a report贸 un d茅ficit patrimonial de 3,9 millones de d贸lares negativos al 31 de marzo de 2025 y ha experimentado p茅rdidas en los 煤ltimos cinco ejercicios fiscales. NYSE American exige un patrimonio neto de 4,0 millones de d贸lares para empresas con p茅rdidas en tres de los 煤ltimos cuatro ejercicios fiscales, y de 6,0 millones para aquellas con p茅rdidas en los 煤ltimos cinco ejercicios. Esta notificaci贸n sigue a una advertencia previa emitida en diciembre de 2024. AIM ha presentado un plan de cumplimiento que fue aceptado por NYSE American, otorg谩ndole hasta el 11 de junio de 2026 para cumplir con los requisitos. Las acciones de la compa帽铆a contin煤an cotizando bajo el s铆mbolo AIM, y la notificaci贸n no afecta sus operaciones comerciales ni los requisitos de reporte ante la SEC.
AIM ImmunoTech a re莽u une notification d鈥檃vertissement de la part de NYSE American en raison du non-respect des exigences minimales en mati猫re de capitaux propres des actionnaires. La soci茅t茅 a d茅clar茅 un d茅ficit des capitaux propres de 3,9 millions de dollars au 31 mars 2025 et a subi des pertes au cours des cinq derniers exercices fiscaux. NYSE American exige des capitaux propres de 4,0 millions de dollars pour les entreprises ayant enregistr茅 des pertes lors de trois des quatre derniers exercices fiscaux, et de 6,0 millions pour celles ayant subi des pertes lors des cinq derniers exercices. Cette notification fait suite 脿 un avertissement pr茅c茅dent 茅mis en d茅cembre 2024. AIM a soumis un plan de conformit茅 qui a 茅t茅 accept茅 par NYSE American, accordant 脿 la soci茅t茅 un d茅lai jusqu鈥檃u 11 juin 2026 pour satisfaire aux exigences. Les actions de la soci茅t茅 continuent d鈥櫭猼re n茅goci茅es sous le symbole AIM, et cette notification n鈥檃ffecte ni ses op茅rations commerciales ni ses obligations de reporting aupr猫s de la SEC.
AIM ImmunoTech hat von der NYSE American eine Verwarnung erhalten, da die Mindestanforderungen an das Eigenkapital der Aktion盲re nicht erf眉llt wurden. Das Unternehmen meldete zum 31. M盲rz 2025 ein negatives Eigenkapital von 3,9 Millionen US-Dollar und verzeichnete in den letzten f眉nf Gesch盲ftsjahren Verluste. Die NYSE American verlangt ein Eigenkapital von 4,0 Millionen US-Dollar f眉r Unternehmen mit Verlusten in drei der letzten vier Gesch盲ftsjahre und 6,0 Millionen US-Dollar f眉r solche mit Verlusten in f眉nf aufeinanderfolgenden Jahren. Diese Mitteilung folgt auf eine vorherige Verwarnung im Dezember 2024. AIM hat einen von der NYSE American akzeptierten Compliance-Plan eingereicht, der dem Unternehmen Zeit bis zum 11. Juni 2026 gibt, um die Anforderungen zu erf眉llen. Die Aktien des Unternehmens werden weiterhin unter dem Symbol AIM gehandelt, und die Mitteilung hat keine Auswirkungen auf den Gesch盲ftsbetrieb oder die SEC-Berichtspflichten.
Positive
Company has until June 11, 2026 to regain compliance
NYSE American has accepted the company's compliance plan
Stock continues trading on NYSE American without interruption
Negative
Stockholders' deficit of negative $3.9 million as of March 31, 2025
Company has reported losses for five consecutive fiscal years
Failed to meet minimum stockholders' equity requirements of both $4.0 million and $6.0 million thresholds
Second warning notice received for the same compliance issue
Insights
AIM faces NYSE American delisting risk due to significant stockholders' deficit and prolonged losses despite having until June 2026 to comply.
The NYSE American notice reveals serious financial challenges for AIM ImmunoTech. The company reported a $3.9 million stockholders' deficit as of March 31, 2025, falling significantly short of the $4.0 million minimum equity requirement for companies with losses in three of four recent fiscal years. Even more concerning, AIM has posted losses for five consecutive fiscal years through December 2024, triggering the higher $6.0 million equity threshold requirement.
This marks AIM's second warning for the same deficiency, following an initial notice in December 2024. The persistent negative equity position signals ongoing difficulties in generating sufficient capital or revenue to offset accumulated losses. While the NYSE American has accepted AIM's compliance plan, giving the company until June 11, 2026, to resolve these deficiencies, the extension merely provides time without addressing the underlying financial weakness.
Despite these compliance issues, AIM's common stock resumed trading on June 17, 2025, under the same ticker symbol. The company emphasizes that the notice doesn't affect daily operations or SEC reporting requirements, which appears to be an attempt to reassure investors. However, the fundamental financial instability indicated by negative equity and sustained losses represents a significant governance concern that could potentially impact long-term viability if not addressed through substantial capital raising, strategic partnerships, or dramatic operational improvements.
NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025
AIM has until June 11, 2026 to regain compliance
OCALA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (鈥淎IM鈥� or the 鈥淐ompany鈥�) (NYSE American: AIM) today announced the receipt of a warning notification (the 鈥淟etter鈥�) from the NYSE American LLC (the 鈥淣YSE American鈥�) stating that the Company is not in compliance with the minimum stockholders鈥� equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the 鈥淐ompany Guide鈥�) requiring stockholders鈥� equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of March 31, 2025, the Company had a stockholders鈥� deficit of negative $3.9 million and has had losses in the most recent five fiscal years ended December 31, 2024.
The NYSE American previously issued a warning on December 17, 2024 for the same reasons and has issued the Letter because the deficiency remains as of March 31, 2025, when the Company filed its quarterly report on Form 10-Q for the first quarter of fiscal 2025.
On February 26, 2025, the NYSE American accepted a plan submitted by the Company to regain compliance by June 11, 2026. Accordingly, the Company still has until June 11, 2026 to regain compliance.
The Company鈥檚 common stock recommenced trading on the NYSE American on June 17, 2025 under the symbol 鈥淎IM鈥�.
The Letter in no way has any effect on such trading and does not affect the Company鈥檚 business, operations or reporting requirements with the U.S. Securities and Exchange Commission.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company鈥檚 lead product is a first-in-class investigational drug called Ampligen庐 (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit聽聽and connect with the Company on聽,听, and聽.
Forward-Looking Statements
This press release contains 鈥渇orward-looking statements鈥� within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management鈥檚 current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥減lan,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥渟hould,鈥� 鈥渢arget,鈥� 鈥渨ill,鈥� or 鈥渨ould鈥� and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company鈥檚 intention to regain compliance with the listing requirements of the NYSE American and its ability to do so. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained herein speak only as of the date hereof, and the Company assumes no聽obligation to update any forward-looking statements, whether as a result of new information, subsequent events or otherwise, except as required by law.
Investor Contact:
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]
FAQ
What are the NYSE American compliance requirements that AIM ImmunoTech (AIM) failed to meet?
AIM failed to meet requirements of $4.0 million stockholders' equity for companies with losses in 3 of 4 recent years, and $6.0 million for those with losses in 5 recent years. The company reported negative $3.9 million stockholders' deficit.
When does AIM ImmunoTech need to regain compliance with NYSE American requirements?
AIM ImmunoTech has until June 11, 2026, to regain compliance with NYSE American's minimum stockholders' equity requirements.
Will AIM stock continue trading on NYSE American despite the noncompliance notice?
Yes, AIM stock continues trading on NYSE American under symbol 'AIM'. The notice does not affect trading or business operations.
What is AIM ImmunoTech's current financial position regarding stockholders' equity?
As of March 31, 2025, AIM ImmunoTech reported a stockholders' deficit of negative $3.9 million and has experienced losses in the five most recent fiscal years.
How many warning notices has AIM received from NYSE American for this issue?
AIM has received two warning notices from NYSE American for the same compliance issue - one on December 17, 2024, and another in June 2025.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
